Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(17):1468-1474; doi:10.1093/jnci/91.17.1468
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Rezza, G.
Right arrow Articles by Ensoli, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rezza, G.
Right arrow Articles by Ensoli, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 17, 1468-1474, September 1, 1999
© 1999 Oxford University Press

REPORTS

Human Herpesvirus 8 Seropositivity and Risk of Kaposi's Sarcoma and Other Acquired Immunodeficiency Syndrome-Related Diseases

Giovanni Rezza, Massimo Andreoni, Maria Dorrucci, Patrizio Pezzotti, Paolo Monini, Roberto Zerboni, Benardino Salassa, Vincenzo Colangeli, Loredana Sarmati, Emanuele Nicastri, Mauro Barbanera, Raffaele Pristerà, Fernando Aiuti, Luigi Ortona, Barbara Ensoli

For the Italian Seroconversion Study

Affiliations of authors: G. Rezza, M. Dorrucci, P. Pezzotti (Centro Operativo AIDS), P. Monini, B. Ensoli (Laboratory of Virology), Istituto Superiore di Sanità, Rome, Italy; M. Andreoni, L. Sarmati, E. Nicastri, Department of Infectious Diseases, University Tor Vergata, Rome; R. Zerboni, Sexually Transmitted Diseases Clinic, University of Milan, Italy; B. Salassa, Infectious Disease Division, Ospedale Amedeo di Savoia, Turin, Italy; V. Colangeli, Infectious Disease Clinic, University of Bologna, Italy; M. Barbanera, Infectious Disease Division, Ospedali Riuniti, Livorno, Italy; R. Pristerà, Infectious Disease Division, Ospedale Regionale, Bolzano, Italy; F. Aiuti, University La Sapienza, Rome; L. Ortona, Catholic University, Rome.

Correspondence to: Barbara Ensoli, M.D., Ph.D., Laboratory of Virology, Istituto Superiore di Sanità, Viale Regina Elena, 299, 00161 Rome, Italy (e-mail: ensoli{at}virus1.net.iss.it), or Giovanni Rezza, M.D., Laboratory of Epidemiology and Biostatistics, Centro Operativo AIDS, Istituto Superiore di Sanità, Viale Regina Elena, 299, 00161 Rome, Italy (e-mail: g.rezza{at}net.iss.it).

BACKGROUND: The incidence of Kaposi's sarcoma (KS) is increased severalfold in individuals infected with human immunodeficiency virus-1 (HIV). Human herpesvirus 8 (HHV8) has also been implicated in KS. We investigated several factors that may determine the onset of KS, particularly HHV8 infection in individuals after becoming seropositive for HIV. METHODS: We studied 366 individuals belonging to different HIV-exposure categories (i.e., homosexual activity, intravenous drug use, and heterosexual contact) for whom a negative HIV serologic test and then a positive HIV serologic test were available within a 2-year period. HHV8 antibody testing was performed by use of an immunofluorescence assay on the first serum sample available after the first positive HIV test. Actuarial rates of progression of KS and of other acquired immunodeficiency syndrome (AIDS)-defining diseases were estimated by use of time-to-event statistical methods. All statistical tests were two-sided. RESULTS: Twenty-one of the 366 study participants developed AIDS-related KS, and 83 developed AIDS without KS. One hundred forty (38.3%) participants had detectable anti-HHV8 antibodies. The actuarial progression rate to KS among persons co-infected with HIV/HHV8 was nearly 30% by 10 years after HIV seroconversion. Increasing HHV8 antibody titers increased the risk of developing KS (for seronegative versus highest titer [1 : 125 serum dilution], adjusted relative hazard [RH] = 51.82; 95% confidence interval [CI] = 6.08-441.33) but not of other AIDS-defining diseases (adjusted RH = 1.14; 95% CI = 0.72-1.80). HHV8-seropositive homosexual men compared with HHV8-seropositive participants from other HIV-exposure categories showed an increased risk of KS that approached statistical significance (adjusted RH = 6.93; 95% CI = 0.88-54.84). CONCLUSIONS: Approximately one third of individuals co-infected with HIV/HHV8 developed KS within 10 years after HIV seroconversion. Progression to KS increased with time after HIV seroconversion. Higher antibody titers to HHV8 appear to be related to faster progression to KS but not to other AIDS-defining diseases.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
E. Ribechini, C. Fortini, M. Marastoni, S. Traniello, S. Spisani, P. Monini, and R. Gavioli
Identification of CD8+ T Cell Epitopes within Lytic Antigens of Human Herpes Virus 8
J. Immunol., January 15, 2006; 176(2): 923 - 930.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
W. H. Navarro and L. D. Kaplan
AIDS-related lymphoproliferative disease
Blood, January 1, 2006; 107(1): 13 - 20.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
E. Trento, C. Castilletti, C. Ferraro, I. Lesnoni La Parola, A. Mussi, L. Muscardin, V. Bordignon, G. D'Agosto, A. Amantea, A. Mastroianni, et al.
Human Herpesvirus 8 Infection in Patients With Cutaneous Lymphoproliferative Diseases
Arch Dermatol, October 1, 2005; 141(10): 1235 - 1242.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
L. Dagna, F. Broccolo, C. T. Paties, M. Ferrarini, L. Sarmati, L. Praderio, M. G. Sabbadini, P. Lusso, and M. S. Malnati
A Relapsing Inflammatory Syndrome and Active Human Herpesvirus 8 Infection
N. Engl. J. Med., July 14, 2005; 353(2): 156 - 163.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
B. R. Lane, J. Liu, P. J. Bock, D. Schols, M. J. Coffey, R. M. Strieter, P. J. Polverini, and D. M. Markovitz
Interleukin-8 and Growth-Regulated Oncogene Alpha Mediate Angiogenesis in Kaposi's Sarcoma
J. Virol., October 11, 2002; 76(22): 11570 - 11583.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. Plancoulaine, L. Abel, M. van Beveren, and A. Gessain
High Titers of Anti-Human Herpesvirus 8 Antibodies in Elderly Males in an Endemic Population
J Natl Cancer Inst, September 4, 2002; 94(17): 1333 - 1335.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Malnati, F. Broccolo, S. Nozza, L. Sarmati, S. Ghezzi, G. Locatelli, F. Delfanti, B. Capiluppi, A. Careddu, M. Andreoni, et al.
Retrospective analysis of HHV-8 viremia and cellular viral load in HIV-seropositive patients receiving interleukin 2 in combination with antiretroviral therapy
Blood, August 13, 2002; 100(5): 1575 - 1578.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
G. Barillari and B. Ensoli
Angiogenic Effects of Extracellular Human Immunodeficiency Virus Type 1 Tat Protein and Its Role in the Pathogenesis of AIDS-Associated Kaposi's Sarcoma
Clin. Microbiol. Rev., April 1, 2002; 15(2): 310 - 326.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Oksenhendler, E. Boulanger, L. Galicier, M.-Q. Du, N. Dupin, T. C. Diss, R. Hamoudi, M.-T. Daniel, F. Agbalika, C. Boshoff, et al.
High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease
Blood, April 1, 2002; 99(7): 2331 - 2336.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
M. Andreoni, L. Sarmati, E. Nicastri, G. El Sawaf, M. El Zalabani, I. Uccella, R. Bugarini, S. G. Parisi, and G. Rezza
Primary Human Herpesvirus 8 Infection in Immunocompetent Children
JAMA, March 13, 2002; 287(10): 1295 - 1300.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. M. BECK, M. J. ROSEN, and H. H. PEAVY
Pulmonary Complications of HIV Infection . Report of the Fourth NHLBI Workshop
Am. J. Respir. Crit. Care Med., December 1, 2001; 164(11): 2120 - 2126.
[Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
E. Toschi, G. Barillari, C. Sgadari, I. Bacigalupo, A. Cereseto, D. Carlei, C. Palladino, C. Zietz, P. Leone, M. Sturzl, et al.
Activation of Matrix-Metalloproteinase-2 and Membrane-Type-1-Matrix-Metalloproteinase in Endothelial Cells and Induction of Vascular Permeability In Vivo by Human Immunodeficiency Virus-1 Tat Protein and Basic Fibroblast Growth Factor
Mol. Biol. Cell, October 1, 2001; 12(10): 2934 - 2946.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
P. Rimessi, A. Bonaccorsi, M. Sturzl, M. Fabris, E. Brocca-Cofano, A. Caputo, G. Melucci-Vigo, M. Falchi, A. Cafaro, E. Cassai, et al.
Transcription Pattern of Human Herpesvirus 8 Open Reading Frame K3 in Primary Effusion Lymphoma and Kaposi's Sarcoma
J. Virol., August 1, 2001; 75(15): 7161 - 7174.
[Abstract] [Full Text]

Home page
 J. Virol.Home page
S. R. Chan and B. Chandran
Characterization of Human Herpesvirus 8 ORF59 Protein (PF-8) and Mapping of the Processivity and Viral DNA Polymerase-Interacting Domains
J. Virol., December 1, 2000; 74(23): 10920 - 10929.
[Abstract] [Full Text]

Home page
 NeurologyHome page
G. Rezza, M. Dorrucci, M. Andreoni, C. Arpino, A. De Luca, P. Monini, E. Nicastri, M. B. Alliegro, P. Pezzotti, and B. Ensoli
Does HHV-8 have a protective role on the development of HIV encephalopathy?
Neurology, December 1, 1999; 53(9): 2032 - 2032.
[Abstract] [Full Text]

Home page
 JNCI J Natl Cancer InstHome page
V. Beral, R. Newton, and F. Sitas
Human Herpesvirus 8 and Cancer
J Natl Cancer Inst, September 1, 1999; 91(17): 1440 - 1441.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.